Replimune (REPL) stock is in focus as the FDA agreed to have a third look at the company's lead drug for melanoma after White House intervention. Read more here.

Thanks to a new collaboration, Replit is giving people a simpler way to make money with their vibe-coded apps and websites.

Visa has announced an undisclosed investment in AI coding platform Replit. The two companies are also exploring how to ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

A beloved burger chain is continuing its steady expansion with four new stores across four states. The four new locations come after the chain announced its plans for growth in late 2025 and opened ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Fraud, waste and abuse of taxpayer funds in California is likely to ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...